Ludger Klimek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3571023/publications.pdf

Version: 2024-02-01

231 papers	14,134 citations	18482 62 h-index	30087 103 g-index
346 all docs	346 docs citations	346 times ranked	9132 citing authors

#	Article	IF	Citations
1	European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020, 58, 1-464.	1.3	1,555
2	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€”2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
3	Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo Journal International, 2014, 23, 282-319.	2.0	338
4	Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 123, 167-173.e7.	2.9	303
5	Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo Journal International, 2017, 26, 16-24.	2.0	292
6	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
7	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1141-1153.	10.7	263
8	Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. Journal of Allergy and Clinical Immunology, 2018, 141, 529-538.e13.	2.9	255
9	Diagnosis and management of <scp>NSAID</scp>â€Exacerbated Respiratory Disease (Nâ€<scp>ERD</scp>)â€”a <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 28-39.	5.7	247
10	Guideline for acute therapy and management of anaphylaxis. Allergo Journal International, 2014, 23, 96-112.	2.0	210
11	Nonâ€allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1657-1665.	5.7	193
12	EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. Journal of Allergy and Clinical Immunology, 2021, 147, 29-36.	2.9	178
13	EAACI Position paper on the standardization of nasal allergen challenges. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1597-1608.	5.7	161
14	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	5.7	160
15	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
16	Guidelines on the management of IgE-mediated food allergies. Allergo Journal International, 2015, 24, 256-293.	2.0	129
17	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
18	The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. Current Allergy and Asthma Reports, 2020, 20, 61.	5.3	127

#	Article	IF	Citations
19	Assessment of clinical efficacy of CYT003â€QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clinical and Experimental Allergy, 2011, 41, 1305-1312.	2.9	125
20	Defining pollen exposure times for clinical trials of allergen immunotherapy for pollenâ€induced rhinoconjunctivitis â€“ an <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 713-722.	5.7	118
21	Intranasal corticosteroids in allergic rhinitis in COVIDâ€19 infected patients: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	5.7	114
22	Perspectives in allergen immunotherapy: 2019 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 3-25.	5.7	113
23	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and Translational Allergy, 2020, 10, 1.	3.2	110
24	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clinical and Translational Allergy, 2018, 8, 45.	3.2	104
25	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
26	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology, 2019, 144, 135-143.e6.	2.9	101
27	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	3.2	97
28	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	3.2	97
29	A compendium answering 150 questions on COVIDâ€19 and SARSâ€CoVâ€2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	5.7	95
30	Treatment of allergic rhinitis using mobile technology with realâ€world data: The <scp>MASK</scp> observational pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1763-1774.	5.7	94
31	<scp>COVID</scp>â€19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste. Laryngoscope, 2021, 131, 1095-1100.	2.0	94
32	Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study. International Archives of Allergy and Immunology, 2011, 154, 336-344.	2.1	93
33	Pilot study of mobile phone technology in allergic rhinitis in European countries: the <scp>MASK</scp>â€rhinitis study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 857-865.	5.7	93
34	Allergenic components of the mRNAâ€1273 vaccine for COVIDâ€19: Possible involvement of polyethylene glycol and IgGâ€mediated complement activation. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3307-3313.	5.7	92
35	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
36	Handling of allergen immunotherapy in the COVIDâ€19 pandemic: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	5.7	87

#	Article	IF	Citations
37	SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Annals of Allergy, Asthma and Immunology, 2015, 114, 134-140.e1.	1.0	84
38	Safety and efficacy of immunotherapy with the recombinant B-cell epitopeâ€"based grass pollen vaccine BM32. Journal of Allergy and Clinical Immunology, 2018, 142, 497-509.e9.	2.9	84
39	The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clinical and Translational Allergy, 2015, 5, 39.	3.2	82
40	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	3.2	81
41	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 837-850.	5.7	79
42	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinicâ€"An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
43	Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update. Allergo Journal International, 2021, 30, 1-25.	2.0	78
44	Perspectives in allergen immunotherapy: 2017 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 5-23.	5.7	76
45	Considerations on biologicals for patients with allergic disease in times of the COVIDâ€19 pandemic: An EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2764-2774.	5.7	75
46	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	2.9	73
47	Challenges in the implementation of <scp>EAACI</scp> guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 64-76.	5.7	72
48	European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 462-472.	5.7	71
49	Intralymphatic Immunotherapy: Update and Unmet Needs. International Archives of Allergy and Immunology, 2019, 178, 141-149.	2.1	71
50	POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clinical and Translational Allergy, 2018, 8, 36.	3.2	70
51	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie Select, 2019, 3, 22-50.	3.1	70
52	Work productivity in rhinitis using cell phones: The <scp>MASK</scp> pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	5.7	69
53	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1622-1631.	5.7	69
54	Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the <scp>EAACI AIT</scp> Guidelines Project. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 816-826.	5.7	67

#	Article	IF	Citations
55	Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 161-166.	2.3	66
56	ARIAâ€EAACI statement on severe allergic reactions to COVIDâ€19 vaccines â€“ An EAACIâ€ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1624-1628.	5.7	66
57	Guidelines of the German Respiratory Society for Diagnosis and Treatment of Adults Suffering from Acute or Chronic Cough. Pneumologie, 2010, 64, 701-711.	0.1	65
58	Comparison of olfactory function in patients with seasonal and perennial allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 1998, 53, 297-301.	5.7	63
59	A randomized placeboâ€controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 272-279.	5.7	59
60	S3-Guideline on allergy prevention: 2014 update. Allergo Journal International, 2014, 23, 186-199.	2.0	58
61	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
62	Recent developments and highlights in allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2274-2289.	5.7	55
63	Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo Journal International, 2021, 30, 51-55.	2.0	55
64	Allergies and COVIDâ€19 vaccines: An ENDA/EAACI Position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2292-2312.	5.7	55
65	Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo Journal International, 2018, 27, 56-65.	2.0	54
66	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp>â€<scp>ARIA</scp>) â€•<scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
67	Adjuvants for immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 648-657.	2.3	52
68	<scp>ARIA</scp> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€• Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
69	Aspirin Intolerance: Does Desensitization Alter the Course of the Disease?. Immunology and Allergy Clinics of North America, 2009, 29, 669-675.	1.9	51
70	Allergic disorders of the respiratory tract â€" findings from a large patient sample in the German statutory health insurance system. Allergo Journal, 2013, 22, 366-373.	0.1	51
71	Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized doseâ€ranging safety study. Clinical and Experimental Allergy, 2012, 42, 936-945.	2.9	50
72	Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy and Asthma Proceedings, 2015, 36, 40-47.	2.2	49

#	Article	IF	Citations
73	Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1â€FV in a randomized controlled trial. Clinical and Translational Allergy, 2015, 5, 28.	3.2	48
74	Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1261-1266.	5.7	48
75	Allergen-Specific Immunotherapy: Which Outcome Measures are Useful in Monitoring Clinical Trials?. Immunology and Allergy Clinics of North America, 2011, 31, 289-309.	1.9	46
76	Clinical use of adjuvants in allergen-immunotherapy. Expert Review of Clinical Immunology, 2017, 13, 599-610.	3.0	46
77	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
78	The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. Journal of Allergy and Clinical Immunology, 1999, 103, 47-53.	2.9	44
79	A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT â€birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 99-107.	5.7	44
80	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	3.8	44
81	Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respiratory Medicine, 2006, 100, 1706-1715.	2.9	43
82	Diagnostic test allergens used for inÂvivo diagnosis of allergic diseases are at risk: a European Perspective. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1329-1331.	5.7	43
83	Stateâ€ofâ€theâ€art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 746-760.	5.7	42
84	Allergen immunotherapy: The growing role of observational and randomized trial â€œRealâ€World Evidenceâ€• Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2663-2672.	5.7	39
85	Epithelialâ€“Mesenchymal Transition in Chronic Rhinosinusitis: Differences Revealed Between Epithelial Cells from Nasal Polyps and Inferior Turbinates. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 157-173.	2.3	38
86	Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo Journal International, 2018, 27, 245-255.	2.0	38
87	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
88	A high polymerized grass pollen extract is efficacious and safe in a randomized doubleâ€blind, placeboâ€controlled study using a novel upâ€dosing clusterâ€protocol. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1629-1638.	5.7	37
89	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 42-44.	1.3	37
90	Is The Allergen Really Needed in Allergy Immunotherapy?. Current Treatment Options in Allergy, 2015, 2, 72-82.	2.2	36

#	Article	IF	Citations
91	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clinical and Translational Allergy, 2017, 7, 37.	3.2	36
92	Current therapeutical strategies for allergic rhinitis. Expert Opinion on Pharmacotherapy, 2019, 20, 83-89.	1.8	36
93	National clinical practice guidelines for allergen immunotherapy: An international assessment applying <scp>AGREE</scp>â€<scp>II</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 664-672.	5.7	35
94	Adrenaline in the Acute Treatment of Anaphylaxis. Deutsches Ärzteblatt International, 2018, 115, 528-534.	0.9	35
95	Pollen season is reflected on symptom load for grass and birch pollenâ€induced allergic rhinitis in different geographic areasâ€"An EAACI Task Force Report. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1099-1106.	5.7	34
96	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. Clinical and Translational Allergy, 2020, 10, 62.	3.2	34
97	Specific Immunotherapy. Deutsches Ärzteblatt International, 2013, 110, 148-58.	0.9	33
98	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
99	Management of patients with chronic rhinosinusitis during the COVIDâ€19 pandemicâ€"An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 677-688.	5.7	33
100	Aspirin Desensitization: Useful Treatment for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Aspirin-Exacerbated Respiratory Disease (AERD)?. Current Allergy and Asthma Reports, 2014, 14, 441.	5.3	32
101	Correlation between work impairment, scores of rhinitis severity and asthma using the MASKâ€airâ„¢ App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	5.7	32
102	Development and validation of combined symptomâ€medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
103	Placebo effects in allergen immunotherapyâ€"An EAACI Task Force Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 629-647.	5.7	31
104	Differentiation of COVIDâ€19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€EAACIâ€GA2LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
105	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASKâ€airÂ®. Clinical and Translational Allergy, 2021, 11, e12062.	3.2	31
106	Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 970-977.	2.9	30
107	Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of) Tj ETQq1 1 0.784314 rgBT /Over Expert Opinion on Pharmacotherapy, 2015, 16, 913-928.	1.8	28
108	Mites and other indoor allergens â€" from exposure to sensitization and treatment. Allergo Journal International, 2015, 24, 68-80.	2.0	28

#	Article	IF	Citations
109	COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) â€“ A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo. Allergologie Select, 2021, 5, 140-147.	3.1	28
110	Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert Review of Clinical Immunology, 2017, 13, 897-906.	3.0	27
111	Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases. World Allergy Organization Journal, 2021, 14, 100498.	3.5	27
112	A new form of irritant rhinitis to filtering facepiece particle (FFP) masks (FFP2/N95/KN95 respirators) during COVID-19 pandemic. World Allergy Organization Journal, 2020, 13, 100474.	3.5	27
113	The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. International Immunology, 2022, 34, 177-188.	4.0	27
114	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Review of Clinical Immunology, 2014, 10, 1059-1067.	3.0	26
115	COVIDâ€19 pandemic and allergen immunotherapyâ€"an EAACI survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3504-3516.	5.7	26
116	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology, 2011, 49, 272-280.	1.3	26
117	Practical handling of allergic reactions to COVID-19 vaccines. Allergo Journal International, 2021, 30, 79-95.	2.0	25
118	Risk of severe allergic reactions to COVIDâ€19 vaccines among patients with allergic skin diseases â€“ practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
119	The Effects of Short-Term Immunotherapy Using Molecular Standardized Grass and Rye Allergens Compared with Symptomatic Drug Treatment on Rhinoconjunctivitis Symptoms, Skin Sensitivity, and Specific Nasal Reactivity. Otolaryngology - Head and Neck Surgery, 2005, 133, 538-543.	1.9	23
120	Intranasal trigeminal sensitivity in subjects with allergic rhinitis. European Archives of Oto-Rhino-Laryngology, 2006, 263, 86-90.	1.6	23
121	Inâ€vivo diagnostic test allergens in Europe: A call to action and proposal for recovery planâ€"An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2161-2169.	5.7	23
122	Telemedicine allows quantitative measuring of olfactory dysfunction in COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 868-870.	5.7	23
123	Technical standards in allergen exposure chambers worldwide â€“ an EAACI Task Force Report. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3589-3612.	5.7	23
124	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	3.1	23
125	Cannabisâ€related allergies: An international overview and consensus recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2038-2052.	5.7	23
126	Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens. International Archives of Allergy and Immunology, 2009, 150, 102-108.	2.1	22

#	Article	IF	Citations
127	Authorised allergen products for intracutaneous testing may no longer be available in Germany. Allergo Journal International, 2015, 24, 84-93.	2.0	22
128	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo Journal International, 2019, 28, 255-276.	2.0	22
129	Practical recommendations for the allergological risk assessment of the COVID-19 vaccination â€“ a harmonized statement of allergy centers in Germany. Allergologie Select, 2021, 5, 72-76.	3.1	22
130	SCIT with aÂhigh-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups. Allergo Journal International, 2018, 27, 131-139.	2.0	21
131	CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance. Frontiers in Immunology, 2021, 12, 590054.	4.8	21
132	New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs). Expert Review of Clinical Immunology, 2016, 12, 1123-1135.	3.0	20
133	Sublingual Immunotherapy Dosing Regimens: What Is Ideal?. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1-10.	3.8	20
134	Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs. American Journal of Rhinology and Allergy, 2013, 27, 206-212.	2.0	19
135	SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. Expert Review of Clinical Immunology, 2016, 12, 369-377.	3.0	19
136	Leitlinie der DGAI zur allergischen Rhinokonjunktivitis. Allergologie, 2003, 26, 147-162.	0.1	19
137	Clinical outcome measures of specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 208-213.	2.3	18
138	Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 630-637.	5.7	18
139	A comparison of immunotherapy delivery methods for allergen immunotherapy. Expert Review of Clinical Immunology, 2013, 9, 465-475.	3.0	17
140	Current practice of allergy diagnosis and the potential impact of regulation in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 323-327.	5.7	17
141	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€air^{Â®} realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
142	Cluster protocols in SCIT: enough evidence for practical use?. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 188-193.	2.3	16
143	Doseâ€response relationship of a new Timothy grass pollen allergoid in comparison with a 6â€grass pollen allergoid. Clinical and Experimental Allergy, 2017, 47, 1445-1455.	2.9	16
144	Evolution of subcutaneous allergen immunotherapy (partÂ1): from first developments to mechanism-driven therapy concepts. Allergo Journal International, 2019, 28, 78-95.	2.0	16

#	Article	IF	Citations
145	Management of anaphylaxis due to COVIDâ€19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	5.7	16
146	Olfaction in patients with allergic rhinitis: an indicator of successful MPâ€AzeFlu therapy. International Forum of Allergy and Rhinology, 2017, 7, 287-292.	2.8	15
147	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis.. Rhinology, 2011, 49, 272-280.	1.3	15
148	Adaptive Desaktivierung bei ASS-intoleranten Patienten mit Polyposis nasi et sinuum Â– MÃ¶glichkeiten eines neuen Therapieprinzips mit intravenÃ¶ser Applikation. Allergologie, 2006, 29, 322-331.	0.1	15
149	Heterogeneity in the Polyclonal T Cell Response to Birch Pollen Allergens. International Archives of Allergy and Immunology, 1997, 114, 272-277.	2.1	14
150	Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. European Archives of Oto-Rhino-Laryngology, 2010, 267, 245-250.	1.6	14
151	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. Expert Opinion on Pharmacotherapy, 2016, 17, 657-669.	1.8	14
152	A possible role of stem cells in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1868-1873.	5.7	14
153	German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. Respiratory Medicine, 2020, 170, 105939.	2.9	14
154	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1805-1812.	3.8	14
155	Effects of allergen immunotherapy in the MASKâ€air study: a proofâ€ofâ€concept analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3212-3214.	5.7	14
156	Olfactory and gustatory disorders in COVID-19. Allergo Journal International, 2022, 31, 243-250.	2.0	14
157	Development of subcutaneous allergen immunotherapy (partÂ2): preventive aspects and innovations. Allergo Journal International, 2019, 28, 107-119.	2.0	13
158	Telemedicine in allergology: practical aspects. Allergo Journal International, 2021, 30, 119-129.	2.0	13
159	Allergic patients during the COVIDâ€19 pandemicâ€”Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey. Clinical and Translational Allergy, 2022, 12, e12097.	3.2	13
160	The Nose as a Route for Therapy: Part 1. Pharmacotherapy. Frontiers in Allergy, 2021, 2, 638136.	2.8	12
161	Nasale Glukokortikosteroid- Therapie: Ein Update. Allergologie, 2011, 34, 307-318.	0.1	12
162	EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1667-1684.	5.7	12

#	Article	IF	Citations
163	COVIDâ€19Â vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€"EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	5.7	12
164	Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2). World Allergy Organization Journal, 2022, 15, 100653.	3.5	12
165	Prevalence of acute olfactory dysfunction differs between variants of SARS-CoV-2â€"results from chemosensitive testing in wild type, VOC alpha (B.1.1.7) and VOC delta (B.1617.2). European Archives of Oto-Rhino-Laryngology, 2022, 279, 5445-5447.	1.6	12
166	A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clinical and Translational Allergy, 2014, 4, 23.	3.2	11
167	Neuronal Differentiation Capability of Nasal Polyps of Chronic Rhinosinusitis. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 431-443.	2.3	11
168	Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing. World Allergy Organization Journal, 2019, 12, 100075.	3.5	11
169	Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clinical and Molecular Allergy, 2020, 18, 15.	1.8	11
170	The influence of European legislation on the use of diagnostic test allergens for nasal allergen provocation in routine care of patients with allergic rhinitis. Rhinology, 2015, 53, 260-269.	1.3	11
171	Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergologie, 2010, 33, 3-33.	0.1	11
172	Eicosanoids, aspirin-intolerance and the upper airways--current standards and recent improvements of the desensitization therapy. Journal of Physiology and Pharmacology, 2006, 57 Suppl 12, 5-13.	1.1	11
173	Management of suspected and confirmed<scp>COVID</scp>â€19 (<scp>SARSâ€CoV</scp>â€2) vaccine hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3426-3434.	5.7	11
174	Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	2.4	10
175	Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs. Clinical and Translational Allergy, 2020, 10, 11.	3.2	9
176	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). Allergologie Select, 2021, 5, 251-259.	3.1	9
177	Anwendung von Biologika bei allergischen und Typ-2- entzÃ¼ndlichen Erkrankungen in der aktuellen COVID-19-Pandemie â€“ ein Positionspapier von AeDA, DGAKI, GPA, Ã–GAI, LGAI, Ã–GP, ARIA und EAACI. Allergologie, 2020, 43, 255-271.	0.1	9
178	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
179	Automatic market research of mobile health apps for the selfâ€management of allergic rhinitis. Clinical and Experimental Allergy, 2022, 52, 1195-1207.	2.9	9
180	Eosinophil Cationic Protein in Nasal Secretions and Blood Serum in Grass-Pollen Allergic Rhinitis. American Journal of Rhinology & Allergy, 1996, 10, 319-322.	2.2	8

#	Article	IF	Citations
181	Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany. Allergo Journal International, 2016, 25, 38-43.	2.0	8
182	Allergen-specific immunotherapy with storage mites. Allergo Journal International, 2018, 27, 15-19.	2.0	8
183	Reliability of a New Symptom Score in a Titrated Quantitative Conjunctival Provocation Test Supported by an Objective Photodocumentation. International Archives of Allergy and Immunology, 2018, 176, 215-224.	2.1	8
184	MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis . Journal of Asthma and Allergy, 2020, Volume 13, 633-645.	3.4	8
185	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Clinical and Experimental Allergy, 2021, 51, 1033-1045.	2.9	8
186	Rupatadin â€“ Pharmakologie, klinische Wirksamkeit und therapeutische Sicherheit eines neuen Antihistamins mit zusÃtzlicher, PAF-antagonisierender Wirkung. Allergologie, 2010, 33, 429-440.	0.1	8
187	Comparison of rhinitis treatments using <scp>MASK</scp>â€airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
188	Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 197-203.	2.3	7
189	Impact of changed legislation on skin tests: the present and future. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 465-468.	2.3	7
190	Course of respiratory allergy by treatment strategy based on German routine data. Allergo Journal International, 2017, 26, 195-203.	2.0	7
191	Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. European Journal of Health Economics, 2018, 19, 1229-1242.	2.8	7
192	A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. Rhinology, 2014, 52, 137-141.	1.3	7
193	In-vitro-Diagnostik des ASS-Intoleranz- Syndroms (Aspirin-exacerbated Respiratory Disease: AERD). Allergologie, 2014, 37, 11-19.	0.1	7
194	Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review. Allergologie Select, 2021, 5, 349-360.	3.1	7
195	ARIA masterclass 2018: From guidelines to real-life implementation. Rhinology, 2019, 57, 0-0.	1.3	6
196	Cluster-Immuntherapie bei allergischer Rhino-Konjunktivitis. Allergologie, 2002, 25, 549-556.	0.1	6
197	Clinical Assessment of Chronic Rhinosinusitis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1406-1416.	3.8	6
198	Allergen immunotherapy during the COVIDâ€19 pandemicâ€"A survey of the German Society for Allergy and Clinical Immunology. Clinical and Translational Allergy, 2022, 12, e12134.	3.2	6

#	Article	IF	Citations
199	Old, Wise and Allergic: Allergies Are No Longer Solely Diseases of the Grandchildren. International Archives of Allergy and Immunology, 2014, 163, 75-76.	2.1	5
200	Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. Allergo Journal International, 2020, 29, 129-138.	2.0	5
201	Rhinitis allergica in storage mite allergy. Allergo Journal International, 2022, 31, 59-68.	2.0	5
202	The benefit of molecular diagnostics in allergic rhinitis. Allergo Journal International, 2017, 26, 301-310.	2.0	4
203	Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP). Allergologie Select, 2022, 6, 148-166.	3.1	4
204	Limited availability of diagnostic allergens for patch testing compromises patient care. JDDG - Journal of the German Society of Dermatology, 2016, 14, 743-745.	0.8	3
205	Allergic reactions to antibiotics â€“ two sides of the same coin: clearly diagnose or reliably rule out. Allergo Journal International, 2017, 26, 212-218.	2.0	3
206	What Do We Really Know About Intralymphatic Immunotherapy?. Current Treatment Options in Allergy, 2018, 5, 415-423.	2.2	3
207	The Debate: Regular Versus As-Needed Use of Intranasal Corticosteroids for a Patient-Centered Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1374-1375.	3.8	3
208	COVIDâ€19 vaccinesâ€”The way forward. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 15-16.	5.7	3
209	Inhaled corticosteroids in early COVIDâ€19â€”A tale of many facets. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3540-3542.	5.7	3
210	Venom Immunotherapy: From Proteins to Product to Patient Protection. Toxins, 2021, 13, 616.	3.4	3
211	Dogmas, challenges, and promises in phase III allergen immunotherapy studies. World Allergy Organization Journal, 2021, 14, 100578.	3.5	3
212	Die adaptive Desaktivierungsbehandlung bei Patienten mit ASS-Intoleranz- Syndrom: Ãœbersicht Ã¼ber ein ursÃchlich- orientiertes Therapieprinzip. Allergologie, 2014, 37, 26-33.	0.1	3
213	AIT mit seltenen Allergenen: Eine (gesundheitspolitische) Bestandsaufnahme. Allergologie, 2018, 41, 416-426.	0.1	3
214	Presentation of airway and general symptoms in COVIDâ€19 caused by dominant <scp>SARSâ€CoV</scp>â€2 variants: A followâ€up on <scp>ARIA</scp> consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3440-3444.	5.7	3
215	Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study. International Archives of Allergy and Immunology, 2020, 181, 754-764.	2.1	2
216	Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4091-4099.	1.6	2

#	Article	IF	Citations
217	Spezifische Immuntherapie (SCIT) mit rekombinanten Allergenen: eine neue Therapieoption bei allergischer Rhinitis. Allergologie, 2008, 31, 503-513.	0.1	2
218	ASS-Intoleranz-Syndrom: Aktuelle Optionen der Therapie. , 0, , .		2
219	Update about OralairÂ® as a treatment for grass pollen allergic rhinitis. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	2
220	Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. Expert Review of Clinical Pharmacology, 2016, 9, 705-714.	3.1	1
221	Current Standards and Improvements in the Use of SLIT Tablets for Allergen Immunotherapy. Current Treatment Options in Allergy, 2017, 4, 286-289.	2.2	1
222	Klinische Parameter zur Beurteilung der Wirksamkeit einer spezifischen Immuntherapie bei polleninduzierter Rhinitis allergica. Bestimmung von â€œwell daysâ€•als ergÃnzendes Konzept. Allergologie, 2010, 33, 35-42.	0.1	1
223	Chronische Rhinosinusitis mit Nasenpolypen: Biologika auf dem PrÃ¼fstand. , 0, , .		1
224	Novel Allergen Immunotherapy Routes. Current Treatment Options in Allergy, 2016, 3, 102-112.	2.2	0
225	Allergologie. , 2009, , 287-309.		0
226	Adaptive Desaktivierung bei Analgetikaintoleranz. , 2016, , 607-612.		0
227	Penicillinallergie (2): Limitierte Diagnostik und ihre Folgen. Deutsches Ärzteblatt International, 0, , .	0.9	0
228	Allergische Rhinitis. , 2019, , 261-269.		0
229	Therapie der allergischen Rhinitis: Polymedikation â€“ Fragen nach der Evidenz. , 0, , .		0
230	Allergische Rhinitis: Der Trend geht zu topischen Therapeutika. , 0, , .		0
231	PrÃzisionsmedizin in der Allergologie: Realistische Erwartungen kommunizieren. , 0, , .		0